Moderna (MRNA) Stock Price, News & Analysis

+3.06 (+2.30%)
(As of 10:15 AM ET)
Today's Range
50-Day Range
52-Week Range
582,851 shs
Average Volume
4.02 million shs
Market Capitalization
$52.11 billion
P/E Ratio
Dividend Yield
Price Target

Moderna MarketRank™ Stock Analysis

Analyst Rating
2.24 Rating Score
4.8% Downside
$126.46 Price Target
Short Interest
6.26% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.67mentions of Moderna in the last 14 days
Based on 34 Articles This Week
Insider Trading
Selling Shares
$18.59 M Sold Last Quarter
Proj. Earnings Growth
From ($7.50) to ($5.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

255th out of 914 stocks

Biological Products, Except Diagnostic Industry

34th out of 153 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report (MRNA)
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report
Could Novavax Become the Next Moderna?
Moderna (NASDAQ:MRNA) Upgraded by Evercore ISI to Hold
Moderna Q1: A Promising Pipeline Is Undervalued
Is This a Setback for Moderna?
Company News For May 13, 2024
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share


Free Float
Market Cap
$50.89 billion

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 2 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

17 Wall Street research analysts have issued 12 month target prices for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they expect the company's share price to reach $126.46 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA stock has increased by 33.6% and is now trading at $132.90.
View the best growth stocks for 2024 here

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our MRNA earnings forecast

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings results on Thursday, May, 2nd. The company reported ($3.07) EPS for the quarter, topping analysts' consensus estimates of ($3.59) by $0.52. The company had revenue of $167 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative trailing twelve-month return on equity of 20.10%. The business's revenue for the quarter was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 earnings per share.

What guidance has Moderna issued on next quarter's earnings?

Moderna updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.66%), Vanguard Group Inc. (10.19%), Capital World Investors (0.95%), Bank of New York Mellon Corp (0.60%), Mawer Investment Management Ltd. (0.50%) and Bellevue Group AG (0.45%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 5/20/2024 by Staff

From Our Partners